Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

montelukast granule

PreclinicalSmall molecule

KKecioren Education and Training Hospital

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bronchopulmonary Dysplasia (BPD)Recruiting

Bronchopulmonary Dysplasia (BPD)Preclinical

Recruiting

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Bronchopulmonary Dysplasia (BPD)

NCT07101640

Clinical

Trials by Indication[1]

Asthma2 trials

Effect of Addition of Single Dose of Oral Montelukast to Standard Treatment in Acute Asthma in Preschool Children.

Completed·KKecioren Education and Training Hospital·Phase 4·NCT01304901·80 enrolled

Effect of Addition Oral Montelukast to Standard Treatment in Acute Asthma in Hospitalized Preschool Children

Completed·KKecioren Education and Training Hospital·Phase 4·NCT03369119·100 enrolled

Bronchopulmonary Dysplasia (BPD)1 trial

Pharmacokinetics, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia

Recruiting·DDuke University·Preclinical·NCT07101640·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for montelukast granule. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — montelukast granule compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for montelukast granule. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kecioren Education and Training Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKecioren Education and Training Hospital

Related News